应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
MAZE Maze Therapeutics
盘前交易 07-23 04:05:16 EDT
16.94
+0.28
+1.68%
最高
17.19
最低
15.17
成交量
13.01万
今开
16.58
昨收
16.66
日振幅
12.12%
总市值
7.42亿
流通市值
2.87亿
总股本
4,380万
成交额
218.51万
换手率
0.77%
流通股本
1,693万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Maze Therapeutics, Inc.2025财年第一财季实现净利润-32.79百万美元，同比减少0.92%
市场透视 · 05-22
Maze Therapeutics, Inc.2025财年第一财季实现净利润-32.79百万美元，同比减少0.92%
异动解读 | Maze Therapeutics成功IPO募资,股价盘中大涨6.25%
异动解读 · 01-31
异动解读 | Maze Therapeutics成功IPO募资,股价盘中大涨6.25%
医疗IPO活跃，今晚Metsera和Maze上市
智通财经 · 01-31
医疗IPO活跃，今晚Metsera和Maze上市
Maze Therapeutics冲刺纳斯达克：拟募资1.3亿美元 路演PPT曝光
雷递网 · 01-28
Maze Therapeutics冲刺纳斯达克：拟募资1.3亿美元 路演PPT曝光
加载更多
公司概况
公司名称：
Maze Therapeutics
所属市场：
NASDAQ
上市日期：
--
主营业务：
Maze Therapeutics, Inc.于2017年8月29日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，利用人类遗传学的力量，为患有肾脏、心血管和相关代谢或CVRM疾病，包括肥胖症的患者开发新颖的小分子精准药物。该公司正在推进使用他们的Compass平台的管道，这使他们能够识别和表征疾病中的遗传变异，然后通过该公司称为变异功能化的过程将这些变异与驱动特定患者群体疾病的生物途径联系起来。他们的罗盘平台专为通过临床试验设计告知药物发现和开发过程的所有阶段而构建。该公司目前正在推进两个全资主导项目，MZE829和MZE782，每一个项目都代表了一种新的基于精准医学的慢性肾病（CKD）方法。
发行价格：
--
{"stockData":{"symbol":"MAZE","market":"US","secType":"STK","nameCN":"Maze Therapeutics","latestPrice":16.94,"timestamp":1753214400000,"preClose":16.66,"halted":0,"volume":130062,"delay":0,"floatShares":16929527,"shares":43797166,"eps":0.33546,"marketStatus":"盘前交易","change":0.28,"latestTime":"07-23 04:05:16 EDT","open":16.58,"high":17.19,"low":15.17,"amount":2185114.694844,"amplitude":0.121248,"askPrice":18,"askSize":100,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.33546,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1753277400000},"marketStatusCode":1,"adr":0,"listingDate":1738299600000,"exchange":"NASDAQ","adjPreClose":16.94,"postHourTrading":{"tag":"盘后","latestPrice":17.1,"preClose":16.94,"latestTime":"18:28 EDT","volume":2087,"amount":35906.14,"timestamp":1753223295797},"volumeRatio":0.872046907222177},"requestUrl":"/m/hq/s/MAZE","defaultTab":"news","newsList":[{"id":"2537923210","title":"Maze Therapeutics, Inc.2025财年第一财季实现净利润-32.79百万美元，同比减少0.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2537923210","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537923210?lang=zh_cn&edition=full","pubTime":"2025-05-23 00:00","pubTimestamp":1747929637,"startTime":"0","endTime":"0","summary":"5月23日，Maze Therapeutics, Inc.公布财报，公告显示公司2025财年第一财季净利润为-32.79百万美元，同比减少0.92%；其中营业收入为0.00美元，每股基本收益为-0.75美元。从资产负债表来看，Maze Therapeutics, Inc.总负债40.77百万美元，其中短期债务4.67百万美元，资产负债比为0.09，流动比率为0.17。机构评级：截至2025年5月23日，当前有3家机构对Maze Therapeutics, Inc.目标价做出预测，其中目标均价为25.00美元，其中最低目标价为19.00美元，最高目标价为28.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000141a48876ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250523000141a48876ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["MAZE","LENZ"],"gpt_icon":0},{"id":"1142675045","title":"异动解读 | Maze Therapeutics成功IPO募资,股价盘中大涨6.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142675045","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142675045?lang=zh_cn&edition=full","pubTime":"2025-02-01 01:22","pubTimestamp":1738344141,"startTime":"0","endTime":"0","summary":"Maze Therapeutics今日股价盘中大涨6.25%,引发市场广泛关注。\n\n消息显示,Maze Therapeutics在今日的IPO中定价为每股16美元,中值于此前公布的定价区间。公司将发行875万股股票,计划募资1.4亿美元。\n\nMaze Therapeutics专注于开发治疗肾脏、心脏和代谢疾病的药物,拥有1.496亿美元的现金储备。该公司的最大股东是Third Rock Ventures的子公司,其他投资者包括ARCH Venture Partners的子公司等知名投资机构。成功IPO将为其持续的药物研发提供资金支持,这可能是促使其股价上涨的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Maze Therapeutics成功IPO募资,股价盘中大涨6.25%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["MAZE"],"gpt_icon":0},{"id":"2507331069","title":"医疗IPO活跃，今晚Metsera和Maze上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2507331069","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507331069?lang=zh_cn&edition=full","pubTime":"2025-01-31 15:40","pubTimestamp":1738309211,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Metsera和Maze Therapeutics这两家制药商在周四公布了首次公开募股定价。根据一份声明，Metsera IPO定价为每股18美元，该公司将出售1530万股股票以筹资2.75亿美元。资料显示，Metsera是一家位于临床阶段的生物技术公司，开发治疗肥胖及相关疾病的注射和口服药物。该公司的最大股东是Third Rock Ventures的子公司，其他投资者包括ARCH Venture Partners的子公司等。在这个1月，Beta Bionics周三进行了2.04亿美元的IPO，亚盛医药于1月23日发行了1.26亿美元的美国存托股票。","market":"sh","thumbnail":"https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/25bb080e73b6be662c435ea6aeaec9c7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1245141.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MTSR","159891","MAZE"],"gpt_icon":0},{"id":"2506566034","title":"Maze Therapeutics冲刺纳斯达克：拟募资1.3亿美元 路演PPT曝光","url":"https://stock-news.laohu8.com/highlight/detail?id=2506566034","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506566034?lang=zh_cn&edition=full","pubTime":"2025-01-28 14:38","pubTimestamp":1738046309,"startTime":"0","endTime":"0","summary":"临床阶段的生物制药公司Maze Therapeutics(股票代码为：“MAZE”)日前更新招股书，准备2025年1月31日在美国纳斯达克上市。Maze Therapeutics发行区间为15美元到17美元，发行780万股，最高募资1.33亿美元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250128/6387367190475143803689168.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20250128/6387367190475143803689168.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n28902/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["LENZ","TSYW.SI","BK1147","BK4139","03086","PPT","TQQQ","NVIW.SI","NQmain","MAZE","ARTL","QLD","SQQQ","USJW.SI","NDX","MNQmain","PSQ","BK4007","USAW.SI",".IXIC","QID"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.mazetx.com","stockEarnings":[{"period":"1week","weight":0.0581},{"period":"1month","weight":0.5152},{"period":"3month","weight":0.7738},{"period":"6month","weight":0.0588},{"period":"ytd","weight":0.0588}],"compareEarnings":[{"period":"1week","weight":0.0108},{"period":"1month","weight":0.0582},{"period":"3month","weight":0.1745},{"period":"6month","weight":0.0313},{"period":"1year","weight":0.1338},{"period":"ytd","weight":0.073}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Maze Therapeutics, Inc.于2017年8月29日根据特拉华州法律成立。该公司是一家临床阶段的生物制药公司，利用人类遗传学的力量，为患有肾脏、心血管和相关代谢或CVRM疾病，包括肥胖症的患者开发新颖的小分子精准药物。该公司正在推进使用他们的Compass平台的管道，这使他们能够识别和表征疾病中的遗传变异，然后通过该公司称为变异功能化的过程将这些变异与驱动特定患者群体疾病的生物途径联系起来。他们的罗盘平台专为通过临床试验设计告知药物发现和开发过程的所有阶段而构建。该公司目前正在推进两个全资主导项目，MZE829和MZE782，每一个项目都代表了一种新的基于精准医学的慢性肾病（CKD）方法。","exchange":"NASDAQ","name":"Maze Therapeutics","nameEN":"Maze Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Maze Therapeutics(MAZE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Maze Therapeutics(MAZE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Maze Therapeutics,MAZE,Maze Therapeutics股票,Maze Therapeutics股票老虎,Maze Therapeutics股票老虎国际,Maze Therapeutics行情,Maze Therapeutics股票行情,Maze Therapeutics股价,Maze Therapeutics股市,Maze Therapeutics股票价格,Maze Therapeutics股票交易,Maze Therapeutics股票购买,Maze Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Maze Therapeutics(MAZE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Maze Therapeutics(MAZE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}